Public Employees Retirement Association of Colorado held its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,017 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Public Employees Retirement Association of Colorado’s holdings in Jazz Pharmaceuticals PLC were worth $1,713,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. US Bancorp DE increased its stake in shares of Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc acquired a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $205,000. Private Advisor Group LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $215,000. Finally, Logan Capital Management Inc. acquired a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $223,000. 86.43% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 142.71 on Friday. The company has a 50 day moving average price of $154.90 and a 200-day moving average price of $146.69. The firm has a market capitalization of $8.57 billion, a PE ratio of 21.83 and a beta of 1.10. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the company earned $2.67 EPS. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post $10.87 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Public Employees Retirement Association of Colorado Has $1,713,000 Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/12/public-employees-retirement-association-of-colorado-has-1713000-position-in-jazz-pharmaceuticals-plc-nasdaqjazz.html.

Several brokerages have weighed in on JAZZ. Cowen and Company reaffirmed an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday. Wells Fargo & Company reaffirmed an “outperform” rating and set a $177.00 target price (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a research note on Thursday. Piper Jaffray Companies reaffirmed a “buy” rating and set a $177.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Thursday. BidaskClub downgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and set a $192.00 target price (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $182.72.

In related news, Director Rick E. Winningham sold 5,000 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $150.00, for a total transaction of $750,000.00. Following the sale, the director now owns 10,391 shares of the company’s stock, valued at approximately $1,558,650. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $160.00, for a total value of $732,800.00. Following the sale, the executive vice president now directly owns 32,322 shares in the company, valued at approximately $5,171,520. The disclosure for this sale can be found here. In the last three months, insiders sold 10,600 shares of company stock worth $1,641,720. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.